{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:44:41Z","timestamp":1767145481838,"version":"build-2238731810"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.clinthera.2017.12.007","type":"journal-article","created":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T19:31:13Z","timestamp":1514489473000},"page":"261-269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Physical Compatibility of Meropenem and Vaborbactam With Select Intravenous Drugs During Simulated Y-site Administration"],"prefix":"10.1016","volume":"40","author":[{"given":"James M.","family":"Kidd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay M.","family":"Avery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomefa E.","family":"Asempa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph L.","family":"Kuti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2017.12.007_bib1","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1007\/s00134-017-4878-x","article-title":"Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach","volume":"43","author":"Bassetti","year":"2017","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.clinthera.2017.12.007_bib2","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1128\/AAC.00711-16","article-title":"Effect of the \u03b2-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae","volume":"60","author":"Castanheira","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2017.12.007_bib3","series-title":"Vabomere (meropenem and vaborbactam for injection) [package insert]","year":"2017"},{"key":"10.1016\/j.clinthera.2017.12.007_bib4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40265-017-0725-1","article-title":"Novel beta-lactamase inhibitors: unlocking their potential in therapy","volume":"77","author":"Wong","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2017.12.007_bib5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1310\/hpj4903-221","article-title":"Understanding and managing intravenous container overfill; potential dose confusion","volume":"49","author":"Cohen","year":"2014","journal-title":"Hosp Pharm"},{"key":"10.1016\/j.clinthera.2017.12.007_bib6","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.2146\/ajhp150721","article-title":"Physical compatibility of tedizolid phosphate with selected i.v. drugs during simulated Y-site administration","volume":"73","author":"Ghazi","year":"2016","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2017.12.007_bib7","first-page":"939","article-title":"Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets","volume":"34","author":"Allen","year":"1977","journal-title":"Am J Hosp Pharm"},{"key":"10.1016\/j.clinthera.2017.12.007_bib8","first-page":"2359","article-title":"Physical compatibility of melphalan with selected drugs during simulated Y-site administration","volume":"50","author":"Trissel","year":"1993","journal-title":"Am J Hosp Pharm"},{"key":"10.1016\/j.clinthera.2017.12.007_bib9","first-page":"1716","article-title":"Turbidimetric assessment of the compatibility of Taxol with selected other drugs during simulated Y-site injection","volume":"49","author":"Trissel","year":"1992","journal-title":"Am J Hosp Pharm"},{"key":"10.1016\/j.clinthera.2017.12.007_bib10","first-page":"300","article-title":"Turbidimetric assessment of the compatibility of Taxol with selected other drugs during simulated Y-site injection, part 2","volume":"50","author":"Trissel","year":"1993","journal-title":"Am J Hosp Pharm"},{"key":"10.1016\/j.clinthera.2017.12.007_bib11","series-title":"Eraxis (anidulafungin injection) [package insert]","year":"2013"},{"key":"10.1016\/j.clinthera.2017.12.007_bib12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2146\/ajhp080059","article-title":"Drug incompatibility chemistry","volume":"66","author":"Newton","year":"2009","journal-title":"Am J Health-Syst Pharm"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2017.12.007_bib13","first-page":"11S","article-title":"Chemical structure and properties of midazolam compared with other benzodiazepines","volume":"16","author":"Gerecke","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2017.12.007_bib14","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.aca.2006.10.015","article-title":"Potentiometric and spectrophotometric pKa determination of water-insoluble compounds: validation study in a new cosolvent system","volume":"583","author":"V\u00f6lgyi","year":"2007","journal-title":"Anal Chim Acta"}],"updated-by":[{"DOI":"10.1016\/j.clinthera.2018.09.013","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000}}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181731113X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181731113X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:49:35Z","timestamp":1758962975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929181731113X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S014929181731113X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.12.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physical Compatibility of Meropenem and Vaborbactam With Select Intravenous Drugs During Simulated Y-site Administration","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}